The results of a recent study show that very low levels of low-density lipoprotein (LDL) cholesterol, known as the "bad" cholesterol, seem to be safe in heart patients who are already taking statins. These patients can see their LDL levels drop from over 200 mg/dL, past the regular target goal of 70 to 80 mg/dL, to as low as 40 mg/dL. The results were published in the October 18, 2005, edition of the Journal of the American College of Cardiology.
Christopher P. Cannon, MD, a cardiologist at Brigham and Women's Hospital in Boston, Mass, and study coauthor, said that the researchers "looked at patients who got to ultra-low cholesterol levels and wanted to make sure that was safe." They found that not only was it safe, but it was actually better to have the levels down near 40 or 50 mg/dL than the previous standard of 70 to 80 mg/dL.
The study involved 1825 patients who were taking statins after having a heart attack or unstable angina. After 4 months of drug therapy, 91% of the patients reported a drop in cholesterol levels to below 100 mg/dL. Of these, 11% saw their levels drop below 40 mg/dL. Compared with the other groups, patients in this percentage group, as well as those whose levels fell between 40 and 60 mg/dL, had fewer heart attacks, strokes, cardiac deaths, chest pains, or other heart problems.
Get to know RESPIMAT, the slow-moving mist inhaler from Boehringer Ingelheim Pharmaceuticals, Inc.
Watch the RESPIMAT video and test your knowledge with a short multiple-choice quiz. When you get all the answers right, you’ll receive a certificate naming you a RESPIMAT T.O.P. Performer. Why not check it out today?
Clinical features with downloadable PDFs